Compare FET & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FET | ANL |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 611.1M |
| IPO Year | 2007 | 2022 |
| Metric | FET | ANL |
|---|---|---|
| Price | $77.42 | $13.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 197.4K | 149.5K |
| Earning Date | 04-30-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | N/A |
| Revenue This Year | $7.35 | $36.02 |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $201.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.53 | $0.88 |
| 52 Week High | $87.42 | $17.25 |
| Indicator | FET | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 62.97 | 57.79 |
| Support Level | $54.55 | $12.45 |
| Resistance Level | N/A | $15.32 |
| Average True Range (ATR) | 4.03 | 1.00 |
| MACD | -0.35 | -0.00 |
| Stochastic Oscillator | 51.61 | 58.24 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.